R121919: Phase II

Researchers published in the Journal of Psychiatric Research data from NBIX’s open-label Phase IIa study of 20 patients in Germany showing that R121919 was well tolerated, did not exhibit endocrinological side effects and had antidepressant activity. Patients in the trial received once daily escalating doses of either 5-40 mg or 40-80 mg of the compound for 30 days. A total of 50 percent of patients in the low dose group and 80 percent of patients in the high dose group had >50 percent reductions in Hamilton Depression scores, and patients also had similar reductions in Hamilton Anxiety scores. A majority of patients experienced a return of depressive symptoms following cessation of therapy, NBIX said. ...